JP MORGAN/PUT/MODERNA/100/0.1/20.09.24 | Market Closed - Bid/Ask 03:00:03 2024-07-16 pm EDT | ||
| 0.23 EUR | -20.69% |
|
| Current month | -23.68% | ||
| 1 month | +61.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.23 | -20.69% |
| 24-07-15 | 0.29 | 0.00% |
| 24-07-12 | 0.29 | +7.41% |
| 24-07-11 | 0.27 | -27.03% |
| 24-07-10 | 0.37 | -7.50% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 03:00 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JB9NS8 |
| ISIN | DE000JB9NS81 |
| Date issued | 2024-01-09 |
| Strike | 100 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 10 : 1 |
| Emission price | 1.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.18 € |
|---|---|
| Lowest since issue | 0.084 € |
| Spread | 0.02 € |
| Spread % | 8.00% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.5
USD
Average target price
145.9
USD
Spread / Average Target
+20.10%
- Stock Market
- Warrants
- Warrant
